48 ADC / Bioconjugation CDMOs

What is ADC / Bioconjugation and when do you need it?

Bioconjugation is the chemistry that joins two molecules into one drug. For an antibody-drug conjugate (ADC), that means covalently attaching a cytotoxic payload to a monoclonal antibody through a linker, so the antibody delivers the toxin selectively to the target cell. A conjugation CDMO is the partner that runs this reaction at the scale and quality your program needs, then purifies the product and controls how many payload molecules end up on each antibody. The same skill set covers other conjugates too: antibody-oligonucleotide conjugates, peptide and protein conjugates, radioconjugates, and PEGylation.

You reach for a conjugation CDMO once you have a lead antibody and a chosen linker-payload, usually as you move from late discovery into IND-enabling and clinical supply. The antibody itself comes from a mammalian cell-culture CDMO, and the payload and linker come from a small-molecule supplier. Conjugation sits in the middle: someone has to bring the naked antibody and the linker-payload together, run the reaction, and release a drug substance that meets spec. That handoff is where most ADC programs get complicated, because three separate supply chains have to converge on one batch.

The decision that defines the whole product is the drug-to-antibody ratio, or DAR. DAR is the average number of payload molecules per antibody, and it drives potency, pharmacokinetics, aggregation, and safety. Conjugation chemistry comes in a few flavors that each control DAR differently: stochastic cysteine or lysine conjugation gives a distribution of DAR species, while site-specific approaches (engineered cysteines, enzymatic tags like microbial transglutaminase or sortase, or glycan remodeling) aim for a tight, homogeneous DAR. The chemistry you pick narrows the list of CDMOs that can actually run it, so settle the conjugation route before you shortlist vendors.

What does an ADC / Bioconjugation CDMO actually do?

A conjugation CDMO takes your purified antibody and your linker-payload and turns them into a defined ADC drug substance, then often carries it through to drug product. The work splits into a few connected jobs, and a single vendor may do all of them or just the conjugation step while you place the antibody and fill-finish elsewhere.

Underneath the headline reaction sits a lot of analytical and process work. The hard part of an ADC is rarely making the bond. It is proving you made the same thing every time: the right DAR, low free payload, controlled aggregation, and a stable molecule that survives storage and shipping. That is why the analytical package and the handling of a highly potent compound matter as much as the chemistry itself.

• Process development: choosing and optimizing the conjugation route (stochastic cysteine or lysine, site-specific, or enzymatic), reduction and reoxidation conditions, buffer and excipient selection, and scaling the reaction from grams to GMP batches.
• Conjugation and purification: running the reaction under controlled conditions, then removing unreacted payload, quenching reagents, and solvent by tangential-flow filtration or chromatography to hit the free-drug and purity limits.
• DAR and analytical characterization: measuring average DAR and the DAR distribution by hydrophobic-interaction chromatography (HIC), reversed-phase, and intact and reduced mass spectrometry, plus aggregate analysis by SEC, residual free payload, and identity and potency assays.
• Highly potent (HPAPI) handling: conjugating cytotoxic payloads such as MMAE, MMAF, DM1, DM4, calicheamicin, PBD dimers, or exatecan derivatives inside containment rated for the payload's occupational exposure band, with the right isolators, ventilation, and waste handling.
• GMP drug substance and drug product: manufacturing conjugated drug substance under GMP, with batch records and release testing, and often sterile fill-finish of the final ADC for clinical or commercial supply.
• Stability and CMC support: forced-degradation and ICH stability studies on a conjugate that can deconjugate or aggregate over time, plus the CMC documentation and method transfer your regulatory filing needs.

How do you choose an ADC / Bioconjugation CDMO?

The first filter is chemistry fit. A CDMO that runs flawless cysteine conjugation may have never executed your enzymatic site-specific route at scale, and a generalist that lists ADCs as one line among many is a different proposition from a dedicated conjugation house. Match the vendor to your exact linker-payload class and conjugation method first, then weigh the practical items below. Price is real, but on an ADC a failed batch of conjugated drug substance, with its scarce antibody and expensive payload consumed, is the costly outcome, not the unit rate.

Run two or three candidates against the same written scope, ideally one that includes a small engineering or non-GMP run before you commit to GMP, so you see how the vendor's process behaves on your molecule rather than on their reference ADC.

• Quality and GxP status: confirm GMP capability for the phase you are in, ask for recent FDA or EMA inspection history, and check that their quality system has carried an ADC through release before, not just a naked antibody.
• HPAPI containment and capacity: verify the facility is rated for your payload's potency band (the occupational exposure limit or OEB), and pin down real batch sizes, the current GMP slot queue, and lead time, since HPAPI suites are scarce and often the binding constraint on your timeline.
• Modality and indication fit: match the conjugation chemistry (stochastic vs site-specific, the specific linker-payload), and confirm experience with your conjugate type, whether that is a classic ADC, an antibody-oligonucleotide conjugate, a radioconjugate, or a bispecific.
• Region and regulatory track record: know where the work is run, whether the site has supported INDs and BLAs or MAAs in your target markets, and how they handle the import-export and licensing that highly potent and, for radioconjugates, radioactive materials require.
• Data quality and analytical depth: ask to see the DAR and impurity methods they would use on your molecule (HIC, mass spec, SEC, free-drug assay), since the analytical package is what proves batch-to-batch consistency and what a reviewer scrutinizes.
• IP and confidentiality, and supply coordination: settle ownership of any process improvements, confirm strong CDA terms, and clarify who coordinates the three-way handoff between the antibody supplier, the linker-payload supplier, and the conjugation site so a delay in one does not strand a GMP slot.